A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 28, 2009

Conditions
Hodgkin DiseaseLymphoma, Non-HodgkinMultiple MyelomaMantle Cell Lymphoma
Interventions
DRUG

Leuprolide acetate depot (LAD) 11.25 mg 3 Month

LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.

DRUG

Matched placebo

Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.

Trial Locations (4)

10021

New York

27710

Durham

63110

St Louis

77030

Houston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Norwood Immunology Limited

UNKNOWN

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Abbott

INDUSTRY